Reddy-ly establishing a European presence

May 2008
Pharmaceutical Technology Europe;May2008, Vol. 20 Issue 5, p9
Trade Publication
The article focuses on the significance of the two European acquisitions of Dr. Reddy's Laboratories Ltd. to its generic pipeline and research and development (R&D) infrastructure. The author claims that the acquisitions could result in cheaper medicines produced by the pharmaceutical company. Dr. Reddy's has recently acquired Jet Generici Srl and Dowpharma Small Molecules, a unit of Dow Chemical Co.


Related Articles

  • Dr. Reddy's Buys Italian Marketing firm. Ramesh, Deepti // Chemical Week;4/14/2008, Vol. 170 Issue 12, p33 

    The article reports on the announcement made by pharmaceutical firm Dr. Reddy's Laboratories of Hyderabad, India that it has acquired Jet Generici Srl of Italy. Financial terms were not disclosed. The acquisition provides access to an essential product portfolio, a pipeline of registration...

  • April March. Sharma, E. Kumar // Business Today;6/1/2008, Vol. 17 Issue 11, p38 

    The article reports on the acquisitions made by Dr Reddy's Laboratories in April 2008. Dr Reddy's Laboratories announced its decision to acquire a portion of Dowpharma Small Molecules Business from Dow Chemical Co. in April 1, 2008. Two days later, the company revealed its takeover of Jet...

  • Dr Reddy's acquires Dow's molecule biz.  // Chemical Business;Apr2008, Vol. 22 Issue 4, p86 

    The article focuses on a definitive agreement entered into by Dr. Reddy's Laboratories Ltd. with the Dow Chemical Co. to acquire a portion of Dowpharma Small Molecules business associated with its sites in Mirfield and Cambridge, England. The acquisition will include the relevant business,...

  • Dr Reddy's Inks commercialisation Deal with Hatchtech.  // eHEALTH;9/16/2015, p1 

    The article reports on the commercialization contract signed by pharmaceutical company Dr. Reddy's Laboratories Ltd. with Australian pharmaceutical company Hatchtech Pty. Ltd., for the development of an innovative prescription head lice product Xeglyze lotion.

  • Dr. Reddy's to acquire select products of Belgian firm, UCB.  // FRPT- Chemical Snapshot;4/19/2015, p14 

    The article reports that Dr. Reddy's Laboratories will purchase some products of biopharmaceutical firm UCB in Maldives, Sri Lanka, Nepal and India in April 2015.

  • Dr. Reddy's completes acquisition of UCB brands.  // FRPT- Chemical Snapshot;7/5/2015, p1 

    The article reports on the acquisition of selected UCB pharmaceutical portfolio by Dr. Reddy's Laboratories in India, Sri Lanka and Maldive to increase presence in the areas of pediatrics, dermatology and neurology.

  • DRL to acquire BMS Laboratories and Meridian Healthcare UK.  // Pharmaceutical Technology Asia;Aug2002, p7 

    Focuses on an agreement signed by Dr Reddy's Laboratories (DRL) to acquire BMS Laboratories Limited and Meridian Healthcare. Impact of the agreement on the expansion efforts of DRL.

  • Beyond betapharm. Sharma, E. Kumar // Business Today;3/21/2010, Vol. 19 Issue 6, p90 

    The article focuses on the emergence of problems after the acquisition of German generics company betapharm Arzneimittel GmbH by Indian pharmaceutical company Dr. Reddy's Laboratories Ltd. It notes that the German government introduced healthcare sector reforms which converted branded generics...

  • OctoPlus Shares Surge After Dr. Reddy's $36M Buyout Bid. Sheridan, Cormac // BioWorld Today;10/23/2012, Vol. 23 Issue 206, p2 

    The article reports on the 27.4 million euro-cash buyout offer accepted by OctoPlus NV from Dr. Reddy's Laboratories Ltd. The event has pushed OctoPlus share price up by 23 percent. Dr. Reddy's is now planning to proceed with a recommended public offer for all the outstanding shares of OctoPlus....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics